Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Rein Therapeutics shares rise after the FDA lifts clinical hold on its Phase 2 RENEW trial for idiopathic pulmonary fibrosis tr...
Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medi...
FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollme...
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Rein Therapeutics (NASDAQ:RNTX) with a Buy rating and a...
